tiprankstipranks
Advertisement
Advertisement
Edgewise Therapeutics initiated with an Outperform at Oppenheimer
PremiumThe FlyEdgewise Therapeutics initiated with an Outperform at Oppenheimer
25d ago
Edgewise Therapeutics price target raised to $51 from $41 at Guggenheim
Premium
The Fly
Edgewise Therapeutics price target raised to $51 from $41 at Guggenheim
28d ago
Edgewise Therapeutics price target raised to $59 from $48 at RBC Capital
Premium
The Fly
Edgewise Therapeutics price target raised to $59 from $48 at RBC Capital
2M ago
Video: SpaceX cements $60B Cursor takeover
PremiumThe FlyVideo: SpaceX cements $60B Cursor takeover
2M ago
Edgewise Therapeutics down 25% at $26.55 after EDG-7500 trial update
Premium
The Fly
Edgewise Therapeutics down 25% at $26.55 after EDG-7500 trial update
2M ago
Edgewise Therapeutics’ EDG-7500 shows improvements in cardiomyopathy
Premium
The Fly
Edgewise Therapeutics’ EDG-7500 shows improvements in cardiomyopathy
2M ago
Edgewise Therapeutics price target raised to $45 from $42 at H.C. Wainwright
PremiumThe FlyEdgewise Therapeutics price target raised to $45 from $42 at H.C. Wainwright
2M ago
Edgewise Gets Buy Rating as Servier Deal Funds Cardiovascular Pivot; $45 Price Target Reaffirmed
Premium
Ratings
Edgewise Gets Buy Rating as Servier Deal Funds Cardiovascular Pivot; $45 Price Target Reaffirmed
2M ago
Edgewise Therapeutics price target raised to $66 from $52 at Raymond James
Premium
The Fly
Edgewise Therapeutics price target raised to $66 from $52 at Raymond James
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100